Drugs / Pracinostat
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02058784 | Feb → Mar 2014 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT03848754 | May 2019 → May 2021 | acute myeloid leukemia | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT03495934 | Feb 2018 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 1 | NCT02118909 | May → Jun 2014 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 1 | NCT01184274 | Oct 2010 → Apr 2012 | cancer, leukemia | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT00504296 | Sep 2007 → Apr 2010 | — | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT00741234 | Apr 2007 → Mar 2012 | cancer, hematopoietic and lymphoid cell neoplasm, myelodysplastic syndrome | S*BIO | Completed | No outcome recorded |
| Phase 28 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03151304 | Jun 2017 → Dec 2020 | myelodysplastic syndrome | Helsinn Healthcare SA | Terminated | No outcome recorded |
| Phase 2 | NCT02267278 | Jan 2015 → Jun 2018 | myeloproliferative neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01912274 | Dec 2013 → Nov 2016 | acute myeloid leukemia | Helsinn Healthcare SA | Completed | Met primary |
| Phase 2 | NCT01993641 | Dec 2013 → May 2015 | myelodysplastic syndrome | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT01873703 | Jun 2013 → Nov 2015 | myelodysplastic syndrome | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT01200498 | Nov 2010 → Nov 2012 | myeloproliferative neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01112384 | Oct 2010 → Jan 2013 | sarcoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01075308 | Jun 2010 → Jan 2015 | prostate cancer | NCIC Clinical Trials Group | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03151408 | Jun 2017 → Aug 2020 | acute myeloid leukemia | Helsinn Healthcare SA | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pracinostat | “Pracinostat (SB939) is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDAC).” PMID 23893953 ↗ Jul 2013 |
| Known as | SB939 | “Pracinostat (SB939) is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDAC).” PMID 23893953 ↗ Jul 2013 |
| Action | Inhibit | “RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT00504296 ↗ |
| Modality | Other / unclassified | “Histone deacetylase inhibitor (HDACi)” NCT01873703 ↗ |
| Route | Oral | “OUTLINE: Patients receive oral SB939 once daily on days 1-5 and 15-19.” NCT00504296 ↗ |